Italia markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
66,85-1,31 (-1,92%)
Al 2:58PM EST. Mercato aperto.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
http://www.gilead.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno11.800

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Daniel P. O'DayChairman & CEO10,86MN/D1964
Mr. Andrew D. DickinsonExec. VP & CFO6,91MN/D1970
Mr. Brett A. PletcherExec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.2,14M1,84M1968
Ms. Johanna MercierChief Commercial Officer2,55MN/D1970
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer1,12MN/D1963
Ms. Diane E. WilfongSr. VP, Corp. Controller & Chief Accounting OfficerN/DN/D1962
Ms. Jyoti K. MehraExec. VP of HRN/DN/DN/D
Dr. William A. LeeExec. VP of ResearchN/DN/D1955
Dr. Taiyin YangExec. VP of Pharmaceutical Devel. & ManufacturingN/DN/D1954
Dr. Diana Brainard M.D.Sr. VP of HIV & Emerging Viral InfectionsN/DN/D1971
Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Governance aziendale

L'ISS Governance QualityScore di Gilead Sciences, Inc. al 22 gennaio 2021 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 2; diritti degli azionisti: 2; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.